… , R ALEXANIAN, HY YAP, AU BUZDAR, F … - Annals of Internal Medicine, 1980 - Am Coll Physicians Thirty-eight patients with advanced breast cancer, multiple myeloma, and
malignant lymphoma were treated with partially purified (about 0.1%) leukocyte
interferon. Patients were treated with a remission-induction schedule of 3 ... Cited by 309 - Related articles - All 2 versions
TC Merigan, K Sikora, JH Breeden, R Levy, … - The New England journal of medicine, 1978 - ncbi.nlm.nih.gov 1: N Engl J Med. 1978 Dec 28;299(26):1449-53. Preliminary observations on the
effect of human leukocyte interferon in non-Hodgkin's lymphoma. ... Cited by 184 - Related articles - All 2 versions
- ►bloodjournal.org [PDF] AC Louie, JG Gallagher, K Sikora, R Levy, … - Blood, 1981 - Am Soc Hematology . Hematology; all rights reserved Copyright 2007 by The American Society of DC
20036. by the American Society of Hematology, 1900 M St, NW, Suite 200,
Washington Blood (print ISSN 0006-4971, online ISSN 1528-0020), is ... Cited by 83 - Related articles - All 3 versions
JU GUTTERMAN, S FINE, J QUESADA, SJ … - Annals of Internal Medicine, 1982 - Am Coll Physicians Sixteen patients with advanced cancer were treated with recombinant-DNA-produced
pure leukocyte A interferon (IFLrA) intramuscularly in doses ranging from 3 to
198 X 10 6 units, with interval periods of 72 to 96 hours between doses. At ... Cited by 278 - Related articles - All 2 versions
EC BORDEN, JF HOLLAND, TL DAO, JU … - Annals of Internal Medicine, 1982 - Am Coll Physicians A multi-institutional trials program was initiated to define the effects of
interferons in disseminated human breast carcinoma. Interferon alpha, prepared
from buffy coats, was administered intramuscularly at 3 x10 6 U daily for ... Cited by 95 - Related articles - All 2 versions
H Mellstedt, M Björkholm, B Johansson, A … - The Lancet, 1979 - Elsevier Four patients with myelomatosis (one IgG-x-type, two IgA-x, and one
Bence-Jones-x) were given human leucocyte interferon as the only treatment for
from 3 to 19 months. Remission was complete in two patients and partial in ... Cited by 171 - Related articles - All 5 versions
KA Foon, SA Sherwin, PG Abrams, DL Longo, … - New England Journal of Medicine, 1984 - content.nejm.org We report the results of a trial of recombinant leukocyte A interferon in
previously treated patients with non-Hodgkin's lymphoma who were no longer
responsive to chemotherapy. Patients received recombinant leukocyte A ... Cited by 171 - Related articles - All 3 versions
JR Quesada, DA Swanson, A Trindade, JU … - Cancer Research, 1983 - AACR Partially purified human leukocyte ( ) interferon was administered im at a dose
of 3 x 10 6 units/day to 19 patients with metastatic renal cell carcinoma. Five
patients (26%) showed partial responses; two patients (10.5%), objective ... Cited by 238 - Related articles - All 2 versions
SJ Horning, JF Levine, RA Miller, SA … - JAMA, 1982 - Am Med Assoc The clinical and immunologic effects of a biosynthetic human leukocyte
interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight
patients with advanced cancer. Single escalating doses from 3 X 10(6) units ... Cited by 71 - Related articles - All 2 versions
JR Quesada, M Hawkins, S Horning, R … - The American journal of medicine, 1984 - Elsevier Fifty-two patients with advanced cancer received sequentially escalating doses
of 3 to 50 million units of recombinant DNA-produced alpha interferon by daily
intramuscular injection. There were 23 patients with metastatic breast ... Cited by 68 - Related articles - All 4 versions
